Pure Global

Namodenoson Treatment of Advanced Pancreatic Cancer - Trial NCT06387342

Access comprehensive clinical trial information for NCT06387342 through Pure Global AI's free database. This Phase 2 trial is sponsored by Can-Fite BioPharma and is currently Not yet recruiting. The study focuses on Pancreatic Adenocarcinoma,Pancreatic Cancer. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06387342
Phase 2
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06387342
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Namodenoson Treatment of Advanced Pancreatic Cancer
CF102-222PC: A Phase 2 Open-Label Study of the Safety and Activity of Namodenoson in the Treatment of Advanced Pancreatic Adenocarcinoma

Study Focus

Namodenoson 25mg

Interventional

drug

Sponsor & Location

Can-Fite BioPharma

Petach Tikva, Israel

Timeline & Enrollment

Phase 2

Jul 15, 2024

Dec 15, 2026

20 participants

Primary Outcome

Adverse Events,Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) Change from baseline

Summary

This is an open-label trial in patients with advanced pancreatic cancer. The trial will
 evaluate the safety, clinical activity, and pharmacokinetics of the study drug, namodenoson,
 in this group of patients.

ICD-10 Classifications

Malignant neoplasm of pancreas
Malignant neoplasm: Pancreas, unspecified
Malignant neoplasm: Head of pancreas
Malignant neoplasm: Other parts of pancreas
Malignant neoplasm: Tail of pancreas

Data Source

ClinicalTrials.gov

NCT06387342

Non-Device Trial